Use of axillary lymph node dissection (ALND) in patients with micrometastatic breast cancer

Given that the risk of lymphedema after ALND ranges between 20%-53%, the morbidity of ALND may far exceed the likelihood of detecting further nodal involvement in women with micrometastatic disease: 7.1% in this series.